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The “Classical Endocrinology” is the fas-
cinating world of endocrine glands, their 
specific hormones and their diseases. This 
encapsulates  the  integration  of  develop-
mental  events  such  as  the  proliferation, 
growth, and differentiation of tissues and 
organs and the coordination of many physi-
ological functions, such as metabolism and 
reproduction, by chemical substances syn-
thesized and secreted by specialized cells. 
A modern view of Endocrinology requires, 
in our opinion, a more detailed sight in 
the field not only of endocrine glands and 
their  diseases,  but  also  of  the  multitude 
of  organs  and  cells  involved,  influenced 
and  eventually  controlled  by  large  intri-
cate pathways of signaling activated by a 
very  heterogeneous  group  of  substances 
targeting  a  wide  spectrum  of  receptors 
and cells throughout the body. Therefore, 
today “Cancer Endocrinology” necessarily 
means focusing on all endocrine tumors 
from classical ones, such as pituitary, thy-
roid, parathyroid, adrenal, and neuroendo-
crine tumors, to types of cancer in which 
endocrine hormones seem to play a relevant 
role such as breast, prostate, ovaries, colon, 
and liver tumors and probably many others. 
As such Cancer Endocrinology should now 
be of particular interest for experimental, 
preclinical, and clinical researchers. Cancer 
Endocrinology now encompases the follow-
ing issues: identification of a definitive role 
for new laboratory tests and radiological 
techniques in diagnosis; identification of 
specific molecular patterns of tumorigen-
esis, which could allow development of new 
directions in the field of pharmacotherapy 
research; combined treatment with conven-
tional treatment options and new molecules 
in preclinical evaluation; synergy between 
chemotherapy and other anticancer modal-
ities,  including  radiotherapy,  immuno-
therapy, and gene therapy; discovery of new 
biomarkers to predict response or resistance 
to drug treatment or to guide the follow-up 
of treated patients.
Examples  of  developments  in  cancer 
endocrinology include the role of soma-
tostatin  (SSTR)  and  dopamine  receptors 
(DR) as molecular targets for the treatment 
of patients with pituitary adenomas and 
neuroendocrine tumors: this has received 
great attention and is leading to innovative 
new therapies. The evidence of expression 
of subtypes of SSTR and DR, as well as of 
co-expression of these receptors in tumor 
cells, has increased the development of new 
experimental drugs, including novel ana-
logs, binding to multiple SSTR subtypes, 
as well as hybrid somatostatin–dopamine 
compounds. These advances have opened 
new perspectives for the medical treatment 
of  pituitary  and  neuroendocrine  tumors 
poorly responsive to conventional thera-
pies and probably also for the treatment of 
other tumor types. Pasireotide (SOM230), 
a novel somatostatin analog with a pecu-
liar receptor binding that makes this analog 
the closest to native somatostatin, is under 
detailed investigation in Cushing’s disease, 
so far an orphan disease for medical therapy. 
Everolimus, an m-TOR inhibitor, indicated 
for treatment of renal carcinoma, has also 
been demonstrated to have some efficacy for 
patients with neuroendocrine tumors sup-
plementing the medical armamentarium for 
management of these patients. Nonetheless, 
today management of aggressive pituitary 
adenomas still remains a challenging clini-
cal problem: new potential therapies such as 
gene therapy, temozolomide, or a combina-
tion of target therapies are foreseen as future 
strategies for these patients.
Another  important  endocrine  axis  to 
be considered in carcinogenesis are repre-
sented by growth factors such as the insu-
lin/insulin-like  growth  factor-I  (IGF  I). 
The IGF system mediates growth, differ-
entiation,  and  developmental  processes. 
Clinical  conditions  associated  with  high 
levels  of  insulin  (non-insulin-dependent 
diabetes mellitus and hypertriglyceridemia) 
and  IGF-I  (acromegaly)  are  related  to 
increased risk of neoplasms, and increased 
circulating concentrations of insulin and 
IGF-I are related to a higher risk of colonic 
neoplasia.  Deregulation  of  IGF  system 
expression and action is linked to differ-
ent diseases, ranging from growth deficits 
to  cancer  development.  Targeting  of  the 
IGF axis has emerged in recent years as a 
promising  therapeutic  approach  in  can-
cer and other conditions. Rational use of 
IGF-I-induced gene signatures may help to 
identify patients who might benefit from 
IGF axis-directed therapeutic modalities. 
IGF-I-induced gene expression in primary 
breast and lung fibroblasts accurately pre-
dict outcomes in breast and lung cancer 
patients. Further studies to investigate the 
role of IGF-pathway on colorectal, prostatic, 
and breast and lung cancer are required.
Classically modulation of gonadal ster-
oids is used as adjuvant treatment in patients 
with breast and prostate cancers. However, 
hypogonadism (as a consequence of ovar-
ian and testicular blockade) causes insulin 
resistance so that patients would probably 
acquire a secondary cause of tumor relapse 
as discussed above. No data are currently 
available on this matter but it is expected 
that  use  of  insulin-sensitizers  (currently 
under  investigation)  would  modify  the 
natural history of breast and prostate can-
cer patients treated with the estrogens or 
androgens blockade.
A separate field of investigation relates 
to the so-called “neuroendocrine degenera-
tion” of some cancers, particularly the pros-
tate. The clinical significance and possible 
treatment approach of tumors with such a 
phenotype is still far from being elucidated.
Lastly, considerable preclinical and epi-
demiologic  data  suggest  that  vitamin  D 
may play a role in the pathogenesis, pro-
gression, and therapy for cancer. The rel-
evance of vitamin D receptor (VDR) gene 
polymorphisms for various types of cancer 
has been widely investigated. It has been 
hypothesized  that  VDR  polymorphisms 
may  influence  both  the  risk  of  cancer 
occurrence and prognosis. However, stud-
ies investigating the associations between 
specific VDR polymorphisms and cancer 
often  show  controversial  results.  Data 
indicating  an  association  of  VDR  poly-
morphisms and cancer risk are relevant for 
breast cancer, prostate cancer, and malig-
nant melanoma. Higher risk of cancer has Frontiers in Endocrinology  | Cancer Endocrinology    March 2011  | Volume 2  | Article 7  |  2
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  multifaceted approach involving genetics, 
cellular and molecular biology, pathophysi-
ology, and oncology would allow a better 
knowledge of endocrine tumor pathogen-
esis and eventually to the development of 
new therapeutic strategies in all the field of 
the “Cancer Endocrinology.”
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through a number of important pathways, 
but the pathway(s) essential to the antitu-
mor activities of vitamin D are unclear. In 
view of the substantial preclinical and epi-
demiologic data supporting the potential 
role of vitamin D in cancer, further studies 
to evaluate the impact of vitamin D replace-
ment on the frequency of cancer and the 
impact of an appropriate dose and schedule 
of treatment are indicated.
The  vitamin  D  and  insulin  axes  are 
also related to the wider argument of the 
nutritional background of cancer, tightly 
linked to the hormonal regulation of cell 
differentiation.
In  conclusion,  the  endocrine  system 
seems to be a key to open the full under-
standing  of  tumoral  development.  A 
been linked with lower serum vitamin D 
levels. Unfortunately, very limited data are 
available to indicate whether or not giving 
vitamin D supplements reduces the risk 
of cancer. Many preclinical studies indi-
cate that exposing cancer cells or vascular 
endothelial cells derived from tumors, to 
high concentrations of vitamin D could 
reduce progression through the cell cycle, 
induce  apoptosis  and  slow  or  stop  the 
growth of tumors in vivo. Despite these 
observations there are no data indicating 
that one type of cancer is more or less sus-
ceptible to the effects of vitamin D. Vitamin 
D also potentiates the antitumor activity 
of a number of types of cytotoxic antican-
cer agents examined in preclinical mod-
els. Vitamin D analogs initiate signaling 